Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stig Lenhoff

Showing results (61-70 of 79) with videos related to

Pageof 8
Sort By:
American Journal of Hematology|October 20, 2022
Allogeneic hematopoietic cell transplantation in patients with chronic phase chronic myeloid leukemia in the era of third generation tyrosine kinase inhibitors: A retrospective study by the chronic malignancies working party of the EBMTYves Chalandon, Giulia Sbianchi, Luuk Gras, et al.
British Journal of Haematology|April 28, 2022
Outcome of allogeneic haematopoietic cell transplantation in eosinophilic disorders: A retrospective study by the chronic malignancies working party of the EBMTDonal P McLornan, Luuk Gras, Ivonne Martin, et al.
Haematologica|December 9, 2017
Melphalan 140 mg/m<sup>2</sup> or 200 mg/m<sup>2</sup> for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working PartyHolger W Auner, Simona Iacobelli, Giulia Sbianchi, et al.
European Journal of Haematology|February 13, 2021
Prognostic impact of early-versus-late responses to different induction regimens in patients with myeloma undergoing autologous hematopoietic cell transplantation: Results from the CALM study by the CMWP of the EBMTLaurent Garderet, Giulia Sbianchi, Simona Iacobelli, et al.
Bone Marrow Transplantation|July 26, 2020
Upfront stem cell transplantation for newly diagnosed multiple myeloma with del(17p) and t(4;14): a study from the CMWP-EBMTNico Gagelmann, Diderik-Jan Eikema, Liesbeth C de Wreede, et al.
American Journal of Hematology|June 21, 2021
Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: A study of the chronic malignancies working party of EBMT and the Spanish Myelofibrosis RegistryJuan-Carlos Hernández-Boluda, Arturo Pereira, Nicolaus Kröger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 21, 2024
Human Leukocyte Antigen Mismatching and Survival in Contemporary Hematopoietic Cell Transplantation for Hematologic MalignanciesEsteban Arrieta-Bolaños, Edouard F Bonneville, Pietro Crivello, et al.
Haematologica|June 30, 2022
Comparison of autologous and allogeneic hematopoietic cell transplantation strategies in patients with primary plasma cell leukemia, with dynamic prediction modelingSarah Lawless, Simona Iacobelli, Nina Simone Knelange, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 23, 2021
IgD Subtype But Not IgM or Non-Secretory Is a Prognostic Marker for Poor Survival Following Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Results From the EBMT CALM (Collaboration to Collect Autologous Transplant Outcomes in Lymphomas and Myeloma) StudySarah Lawless, Giulia Sbianchi, Curly Morris, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 7, 2016
Comparison of Intensive Chemotherapy and Hypomethylating Agents before Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndromes: A Study of the Myelodysplastic Syndrome Subcommittee of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplant ResearchVictoria T Potter, Simona Iacobelli, Anja van Biezen, et al.
Pageof 8

Showing results (61-70 of 79) with videos related to

Sort By:
Pageof 8
American Journal of Hematology|October 20, 2022
Allogeneic hematopoietic cell transplantation in patients with chronic phase chronic myeloid leukemia in the era of third generation tyrosine kinase inhibitors: A retrospective study by the chronic malignancies working party of the EBMTYves Chalandon, Giulia Sbianchi, Luuk Gras, et al.
British Journal of Haematology|April 28, 2022
Outcome of allogeneic haematopoietic cell transplantation in eosinophilic disorders: A retrospective study by the chronic malignancies working party of the EBMTDonal P McLornan, Luuk Gras, Ivonne Martin, et al.
Haematologica|December 9, 2017
Melphalan 140 mg/m<sup>2</sup> or 200 mg/m<sup>2</sup> for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working PartyHolger W Auner, Simona Iacobelli, Giulia Sbianchi, et al.
European Journal of Haematology|February 13, 2021
Prognostic impact of early-versus-late responses to different induction regimens in patients with myeloma undergoing autologous hematopoietic cell transplantation: Results from the CALM study by the CMWP of the EBMTLaurent Garderet, Giulia Sbianchi, Simona Iacobelli, et al.
Bone Marrow Transplantation|July 26, 2020
Upfront stem cell transplantation for newly diagnosed multiple myeloma with del(17p) and t(4;14): a study from the CMWP-EBMTNico Gagelmann, Diderik-Jan Eikema, Liesbeth C de Wreede, et al.
American Journal of Hematology|June 21, 2021
Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: A study of the chronic malignancies working party of EBMT and the Spanish Myelofibrosis RegistryJuan-Carlos Hernández-Boluda, Arturo Pereira, Nicolaus Kröger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 21, 2024
Human Leukocyte Antigen Mismatching and Survival in Contemporary Hematopoietic Cell Transplantation for Hematologic MalignanciesEsteban Arrieta-Bolaños, Edouard F Bonneville, Pietro Crivello, et al.
Haematologica|June 30, 2022
Comparison of autologous and allogeneic hematopoietic cell transplantation strategies in patients with primary plasma cell leukemia, with dynamic prediction modelingSarah Lawless, Simona Iacobelli, Nina Simone Knelange, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 23, 2021
IgD Subtype But Not IgM or Non-Secretory Is a Prognostic Marker for Poor Survival Following Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Results From the EBMT CALM (Collaboration to Collect Autologous Transplant Outcomes in Lymphomas and Myeloma) StudySarah Lawless, Giulia Sbianchi, Curly Morris, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 7, 2016
Comparison of Intensive Chemotherapy and Hypomethylating Agents before Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndromes: A Study of the Myelodysplastic Syndrome Subcommittee of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplant ResearchVictoria T Potter, Simona Iacobelli, Anja van Biezen, et al.
Pageof 8